New hope for tough blood cancers: first patients test experimental drug
NCT ID NCT06359002
Summary
This is the first time a new drug called BYON4413 is being tested in people. The study aims to find a safe dose and see if it helps patients with acute myeloid leukemia or myelodysplastic syndromes that have returned or not responded to standard treatments. It will first test increasing doses in a small group to check safety, then give that dose to more people to look for early signs that the drug works against the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Het Ziekenhuisnetwerk Antwerpen
Antwerp, Belgium
-
Hospital Clinic de Barcelona
Barcelona, Spain
-
Hospital San Pedro de Alcantara
Cáceres, Spain
-
Hospital Universitario de Salamanca
Salamanca, Spain
-
Hospital Universitario y Politecnico La Fe
Valencia, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
-
Institut Catala d'Oncologia
Badalona, Spain
-
UZ Leuven
Leuven, Belgium
-
Universitair Medisch Centrum Groningen
Groningen, Netherlands
Conditions
Explore the condition pages connected to this study.